MétaCan
Menu
Back to cohort
Record W2622354226 · doi:10.1002/hon.2437_76

CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP

2017· article· en· W2622354226 on OpenAlexaffabout
John Kuruvilla, M. Crump, Diego Villa, Muhammad Imran Aslam, Anca Prica, David W. Scott, Nanees Abd-Elsamad, Stephen Couban, Stéphane Doucet, Jill Dudebout, Isabelle Fleury, Graeme Fraser, Jean-François Larouche, Mona Shafey, Pamela Skrabek, Tanya Skamene, Chad Winch, L. E. Shepherd, B.E. Chen, Annette E. Hay

Bibliographic record

VenueHematological Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicChronic Lymphocytic Leukemia Research
Canadian institutionsCanadian Cancer Society
Fundersnot available
KeywordsMedicineInternal medicineRituximabSalvage therapyInterim analysisOncologyClinical endpointGemcitabineFebrile neutropeniaDiffuse large B-cell lymphomaPopulationNeutropeniaIbrutinibChemotherapy regimenSurgeryChemotherapyRandomized controlled trialLymphomaLeukemia

Abstract

fetched live from OpenAlex

Introduction: Salvage chemotherapy and ASCT remains the standard of care in patients (pts) with relapsed/refractory (RR) DLBCL. CCTG trial LY.12 established rituximab combined with gemcitabine, dexamethasone and cisplatin (R-GDP) as a standard of care in this population (Crump JCO 2014), with a low incidence of febrile neutropenia (12%) and infection. Methods: CCTG LY.17 is an ongoing multi-arm randomized phase II “pick a winner” trial evaluating novel salvage therapy and R-GDP in RR-DLBCL pts post rituximab and anthracycline based chemotherapy failure. The first experimental arm evaluated ibrutinib 560 mg PO daily d1-21 with R-GDP (IR-GDP) q3W. Primary endpoint of the study is overall response rate (ORR) after 3 cycles of therapy using CT imaging (FDG-PET response is an exploratory endpoint). According to the protocol futility rule, any treatment arm with an ORR lower than the control arm at the first interim analysis (n = 16) is not considered worthy of further testing and enrolment in that arm will cease. After the run-in cohort of the first 5 IR-GDP pts suggested an increased risk of infection, twice weekly blood count monitoring and antimicrobial prophylaxis for opportunistic infection was recommended along with consideration of G-CSF support. This report is the result of the first interim analysis reporting on 30 pts. Results: Baseline pt characteristics are reported in Table 1. In the IR-GDP arm 11/14 pts received an ibrutinib dose intensity of >90%. The ORR to IR-GDP was 28.6% (CR 0, PR 28.6%, SD 28.6%, PD 14.3%, inevaluable 28.6%). 8 SAEs including 2 grade 5 events (1 sepsis, 1 pneumonia) and 3 grade 3 infectious events were reported in the IR-GDP arm. Median neutrophil and lymphocyte counts were 1.75 (0.9-20.7) and 0.23 (0.15-0.3) at time of onset of infection. The ORR to R-GDP was 50.1% (CR 6.3%, PR 43.8%, SD 12.5%, PD 37.5%, inevaluable 0). Among patients assigned to R-GDP there were no infections grade 3 or higher; there were 4 SAEs and no grade 5 events. At the time of database lock (median f/u 3.5 months, range 0.7-9.2), all patients were off protocol treatment (IR-GDP:R-GDP; death 2:0;, AE 1:0, PD prior to completion of protocol therapy 1:4; patient choice 0:1 and treatment complete 10:11) with 19 pts having a progression event (IR-GDP:R-GDP; on treatment 3:3; during follow-up 5:5; death without PD 2:1) and 11 alive without PD (IR-GDP 4, R-GDP 7). Conclusions: Addition of ibrutinib did not improve the activity of R-GDP and appeared to be associated with increased risk of infection; accrual to this arm has ceased and additional combinations are being explored. Keywords: diffuse large B-cell lymphoma (DLBCL); ibrutinib; salvage treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.365
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0120.003
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0070.001
Bibliometrics0.0010.000
Science and technology studies0.0010.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.136
GPT teacher head0.443
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueHematological OncologySame topicChronic Lymphocytic Leukemia ResearchFrench-language works237,207